| Summary: | Our aims in this work are the preparation of an ionic liquid based on heterocyclic compounds with Ag nanoparticles and the investigation of its application as an antibacterial and anticandidal agent. These goals were achieved through the fabrication of an ionic liquid based on Ag nanoparticles with 5-Amino-3-(4-fluorophenyl)-N-hexadecyl-7-(4-methylphenyl)-2-H spiro[cyclohexane1,2’-[1,3]thiazolo [4,5-b]pyridine]-6-carbonitrile (<b>P16</b>). The nanostructure of the prepared ionic liquid was characterized using techniques such as FTIR, <sup>1</sup>HNMR, <sup>13</sup>CNMR, UV, SEM, and TEM. The biological activity of the prepared compound (<b>P16</b>) and its nanocomposites with Ag nanoparticles was tested using five clinical bacteria (<i>Pseudomonas aeruginosa</i> 249; <i>Escherichia coli</i> 141; <i>Enterobacter</i> cloacae 235; <i>Staphylococcus epidermidis</i> BC 161, and methicillin-resistant <i>S. aureus</i> 217), and three Candida species (<i>Candida utilis</i> ATCC 9255; <i>C. tropicalis</i> ATCC 1362, and <i>C. albicans</i> ATCC 20402). The FTIR, <sup>1</sup>HNMR, and <sup>13</sup>CNMR results confirmed the chemical structure of the synthesized <b>P16</b> compound. The nanostructure of the prepared ionic liquid was determined based on data obtained from the UV, SEM, and TEM tests. The antibacterial and anticandidal results showed that the biological activity of the compound (<b>P16</b>) was enhanced after the formation of nanocomposite structures with Ag nanoparticles. Moreover, the biological activity of the compound itself (<b>P16</b>) and that of its nanocomposite structure with Ag nanoparticles was higher than that of ampicillin and amphotericin B, which were used as control drugs in this work.
|
|---|